Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients
- 1 March 2007
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Endocrinology & Metabolism
- Vol. 3 (3) , 260-269
- https://doi.org/10.1038/ncpendmet0449
Abstract
The two major steps of iodine metabolism--uptake and organification--are altered in thyroid cancer tissues. Organification defects result in a rapid discharge of radioiodine from thyroid cells, a short effective half-life of iodine, and a low rate of thyroid hormone synthesis. These defects are mainly due to decreased expression of functional genes encoding the sodium-iodide symporter and thyroid peroxidase and could result in a low radiation dose to thyroid cancer cells. TSH stimulation that is achieved with injections of recombinant human TSH, or long-term withdrawal of thyroid hormone treatment increases iodine-131 uptake in two-thirds of patients with metastatic disease and increases thyroglobulin production in all patients with metastases, even in the absence of detectable uptake. Serum thyroglobulin determination obtained following TSH stimulation and neck ultrasonography is the most sensitive combination for the detection of small tumor foci. Radioiodine treatment is effective when a high radiation dose can be delivered (in patients with high uptake and retention of radioiodine) and when tumor foci are sensitive to the effects of radiation therapy (younger patients, with a well-differentiated tumor and/or with small metastases). The other patients rarely respond to radioiodine treatment, and when progression occurs, other treatment modalities should be considered. Novel strategies are currently being explored to restore iodine uptake in cancer cells that are unable to concentrate radioiodine.Keywords
This publication has 66 references indexed in Scilit:
- Three-Dimensional Organization of Thyroid Cells into Follicle Structures Is a Pivotal Factor in the Control of Sodium/Iodide Symporter ExpressionEndocrinology, 2006
- Modulation of Thyroid-Specific Gene Expression in Normal and Nodular Human Thyroid Tissues from Adults: An in Vivo Effect of ThyrotropinJournal of Clinical Endocrinology & Metabolism, 2005
- Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissuesJournal of Endocrinological Investigation, 2004
- Evidence for Transcriptional and Posttranscriptional Alterations of the Sodium/Iodide Symporter Expression in Hypofunctioning Benign and Malignant Thyroid TumorsThe American Journal of Pathology, 2004
- Expression of the Apical Iodide Transporter in Human Thyroid Tissues: A Comparison Study with Other Iodide TransportersJournal of Clinical Endocrinology & Metabolism, 2004
- The Sodium/Iodide Symporter (NIS): Characterization, Regulation, and Medical SignificanceEndocrine Reviews, 2003
- Identification and Characterization of a Putative Human Iodide Transporter Located at the Apical Membrane of ThyrocytesJournal of Clinical Endocrinology & Metabolism, 2002
- Cloning of Two Human Thyroid cDNAs Encoding New Members of the NADPH Oxidase FamilyJournal of Biological Chemistry, 2000
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998
- Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS)Nature Genetics, 1997